Posted by Michael Wonder on 21 Sep 2025
KalVista Pharmaceuticals announces European Commission and Swissmedic approval of Ekterly (sebetralstat), first and only oral on-demand treatment for hereditary angioedema
19 September 2025 - First European launch of Ekterly expected in Germany Q4, 2025.
KalVista Pharmaceuticals today announced that the European Commission and the Swiss Agency for Therapeutic Products (Swissmedic) have approved Ekterly (sebetralstat), a novel, oral plasma kallikrein inhibitor, for the symptomatic treatment of acute attacks of hereditary angioedema in adults and adolescents aged 12 years and older.
